Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...

The acquisition includes clinical-stage HS235, an investigational therapy targeting pulmonary hypertension and related heart conditions.

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026 ...

Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as ...

The interplay between host immunity, the microbiota, and cancer is a rapidly evolving area of immuno-oncology. An increasing body of evidence highlights the ...

Madrigal has made three in-licensing deals since July 2025, picking up multiple potential MASH therapeutics. Read why MDGL ...